Ptc Therapeutics (PTCT) Non-Current Deffered Revenue (2012 - 2020)

Ptc Therapeutics' Non-Current Deffered Revenue history runs 7 years deep, the most recent figure standing at $1.8 million for Q1 2020.

• On a quarterly basis, Non-Current Deffered Revenue fell 80.03% year-over-year to $1.8 million in Q1 2020; TTM through Mar 2020 was $1.8 million, a 80.03% decrease from a year earlier, with the FY2019 full-year figure at $3.4 million, down 64.87% from the prior year.
• Non-Current Deffered Revenue fell to $1.8 million in Q1 2020 per PTCT's latest filing, from $3.4 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $11.2 million in Q3 2018 and bottomed at $1.6 million in Q4 2016.
• The 5-year median for Non-Current Deffered Revenue is $7.2 million (2017), against an average of $6.4 million.
• Across the five-year window, Non-Current Deffered Revenue surged 401.2% in 2017 and tumbled 80.03% in 2020, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $1.6 million in 2016, then jumped by 401.2% to $8.0 million in 2017, then rose by 22.23% to $9.7 million in 2018, then tumbled by 64.87% to $3.4 million in 2019, then tumbled by 48.23% to $1.8 million in 2020.
• Per Business Quant, the three latest PTCT Non-Current Deffered Revenue figures stand at $1.8 million (Q1 2020), $3.4 million (Q4 2019), and $5.5 million (Q3 2019).